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Acute-phase response is an inflammatory 
process mainly triggered by the cytokine 
interleukin-6 (IL-6). Signaling of IL-6 is 
transduced by the activation of the signal 
transducer and activator of transcription 
(STAT)3, that rapidly induces the production 
of acute-phase proteins such as haptoglobin 
(Hp) and fibrinogen. Another target of the 
IL-6-STAT3 signal transduction pathway is the 
microRNA (miRNA) cluster miR-17/92. Here, 
we investigated the interplay of miR-17/92 and 
STAT3 signaling and its impact on the acute-
phase response in primary human hepatocytes 
and hepatoma (HepG2) cells. Employing a 
reporter gene system consisting of STAT3 
sensitive promoter sequences, we show that the 
miR-17/92 cluster member miR-18a enhanced 
the transcriptional activity of STAT3. IL-6 
stimulation experiments in miR-18a over 
expressing hepatocytes and HepG2 cells 
revealed an augmented acute-phase response 
indicated by increased expression and secretion 
of Hp and fibrinogen. This effect was, at least in 
part, due to the repression of the protein 
inhibitor of activated STAT 3 (PIAS3), a 
repressor of STAT3 activity, which we 
identified as a novel direct target of miR-18a. 
Finally, we demonstrate that the expression of 
miR-17/92 in primary hepatocytes and HepG2 
cells is modulated by IL-6. Our data reveal for 
the first time a miRNA mediated positive 
feedback loop of IL-6 signal transduction 
leading to an enhanced acute-phase response in 
human hepatocytes. 
 
    Severe inflammation is observed in several 
conditions including overwhelming infection, 
systemic-inflammatory response syndrome 
(SIRS), sepsis, and septic shock and results in the 
activation of a signaling cascade that is commonly 
referred to as acute-phase response. Acute-phase 
proteins are involved in a great variety of 
physiological and biochemical processes including 
growth inhibition of microbes (e. g. complement 
factors), blood coagulation (e. g. fibrinogen), and 
binding of proteins (e. g. haptoglobin-mediated 
binding of hemoglobin) (1). During inflammation, 
the production of plasma proteins by hepatocytes 
is altered, either by increasing the levels of plasma 
proteins (positive acute-phase reaction) or by 
decreasing their levels (negative acute-phase 
reaction).  
    Interleukin-6 (IL-6) is one of the most important 
cytokines that orchestrates the hepatic production 
of acute-phase proteins (2). For signal 
transduction, IL-6 binds to a membrane associated 
receptor complex, which subsequently leads to the 
phosphorylation of tyrosine residue 705 (Tyr705) 
of the signal transducer and activator of 
transcription (STAT)3 (3). Phosphorylated STAT3 
is actively transported to the nucleus where it 
activates the transcription of IL-6 target genes 
such as the acute-phase genes haptoglobin (Hp) 
(4) and fibrinogen gamma chain (FGG) (5). 
Several negative feedback loops antagonize the 
activation of STAT3 to avoid persistent 
downstream signaling and subsequent 
dysregulation in the production of acute-phase 
proteins. A well characterized feedback pathway 
includes the blocking of the phosphorylation of 
STAT proteins by the action of the cytokine 
inducible family of suppressors of cytokine 
signaling (SOCS) (6). 
    MicroRNAs (miRNAs) comprise a novel class 
of short non-protein-coding RNAs that regulate 
the expression of their target genes in a post-
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transcriptional manner either by mRNA 
degradation or by translational repression (7). The 
importance of miRNAs in the signal transduction 
of IL-6 has been highlighted by a recent study 
showing that miRNAs derived from the miRNA 
cluster miR-17/92 modulate STAT3 
phosphorylation in multiple myeloma cells (8); 
moreover, Fort and co-workers identified several 
miRNAs that are directly involved in the 
production of the acute-phase protein fibrinogen in 
human hepatoma (HuH7) cells (9). The 
polycistronic miRNA cluster miR-17/92 codes for 
six mature miRNAs (miR-17-5p, miR-18a, 
miR-19a, miR-19b, miR-20a, and miR-92) and has 
primarily attracted attention for being frequently 
linked to cancer by exhibiting oncogenic activities 
mainly due to targeting tumor suppressor genes 
(10). The expression of miR-17/92 is regulated by 
a number of known transcription factors including 
the oncogenic transcription factor c-Myc (11). In a 
previous work we provided evidence that, upon 
stimulation with IL-6, the expression of 
miR-17/92 is directly regulated by STAT3 thus 
emphasizing a potential link between miR-17/92 
and inflammatory processes (12). Based on these 
findings we hypothesized that miR-17/92 might 
represent a key player in IL-6 signal transduction 
contributing to the regulation of the acute-phase 
response in hepatocytes.  
    Since hepatocellular carcinoma (HepG2) cells 
have been extensively used to investigate the IL-6 
induced expression of acute-phase proteins and, 
thus, provide an established model to study the 
acute-phase response (13), we used these cells in 
the present study to address the role of miR-17/92 
for expression of acute-phase genes and to identify 
novel miR-17/92 targets in the IL-6 signaling 
cascade. In addition, the interaction between miR-
17/92 and the acute-phase response was 
investigated in primary human hepatocytes to 
underscore the role of these miRNAs in a 
physiological setting. Our data reveal for the first 
time a miRNA mediated positive feedback loop of 
the IL-6 signal transduction leading to an 





Methods are described in detail in the online 
supplement. 
Cell culture- Human hepatocellular carcinoma 
(HepG2) cells and human embryonic kidney 
(HEK)293 cells were grown in Dulbecco’s 
modified Eagle’s medium supplemented with 10% 
fetal calf serum. Human primary hepatocytes were 
purchased from Lonza (Lonza, Verviers, Belgium) 
and cultured according to the manufacturer’s 
instructions. For stimulation experiments, HepG2 
cells and primary hepatocytes were serum starved 
for 24h and treated with IL-6 as indicated. 
Quantitative real time-PCR (qPCR) analysis- 
Quantification of specific messenger RNA 
transcripts (mRNA) was performed by SYBR 
Green qPCR using the ABI Prism 7700 Sequence 
Detection System (Applied Biosystems, Rotkreuz, 
Switzerland) with normalization to the expression 
of glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH). Mature miRNAs were detected by 
specific stem-loop primers according to Chen et 
al. (14). Primer sequences are shown in Suppl. 
Table S1. 
Western blot- The following primary antibodies 
were used: anti – PIAS3, anti – Hp (both from 
Abcam, Cambridge, UK), anti - STAT3 (R&D 
Systems), anti – Phospho-STAT3 (Tyr705, Cell 
Signaling Technology, Danvers MA, USA), and 
anti – α-tubulin (Sigma, St. Louis, MO, USA). 
Bands were detected with species-specific 
secondary antibodies coupled to horseradish 
peroxidase and quantified with the Alpha Imager 
software (Alpha Innotech, San Leandro, CA, 
USA). 
Plasmid construction- An 878-bp-fragment of the 
Hp promoter containing two STAT3 binding sites 
and 578 bp of the FGG promoter (one STAT3 
binding site) were each cloned into the firefly 
luciferase-based pGL3basic vector (Promega, 
Dübendorf, Switzerland). The SV40 promoter of 
pRL-SV40 (Promega) was replaced by the 
promoter of GAPDH (1063 bp). The 
3’untranslated region (UTR) of PIAS3 (924 bp) 
was cloned into the pGL3control vector 
(Promega). As negative control, the anti-sense 
construct was used (15) as well as a construct with 
the specifically mutated seed match for miR-18a.  
Reporter gene assay- For promoter activity 
studies, HepG2 cells were transfected with 
pGL3basic-Hp or pGL3basic-FGG, and pRL-
GAPDH for normalization. After 24h, the cells 
were stimulated with IL-6 for 4h. Luciferase 
activity was measured using the Dual-Luciferase 
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Reporter Assay System (Promega) and normalized 
to the activity of Renilla luciferase. 
    For miRNA target validation, HEK293 cells 
were transfected with pGL3control-PIAS3-3’UTR, 
pRL-SV40 for normalization, and precursor 
molecules of miRNAs (pre-miRs). After 24h, the 
cells were lysed, and luciferase activity was 
measured using the Dual-Luciferase Reporter 
Assay System.  
Transfection of small interfering RNAs (siRNAs) 
and miRNAs- HepG2 cells were transfected with 
200nM of siRNAs (Qiagen, Hombrechtikon, 
Switzerland) or 100nM of pre-miRs or anti-miRs 
(Ambion/Applied Biosystems; pre-miR-18a, -19a, 
-20a, -92a or anti-miR-18a) using the cell line 
nucleofector kit V (Amaxa, Cologne, Germany) or 
Lipofectamine 2000. Following an incubation 
period of 48h or 72h, cells were stimulated with 
IL-6 (20ng/ml). 
Enzyme-linked immunosorbent assay (ELISA)- To 
determine levels of Hp and fibrinogen in cell 
culture supernatants commercially available 
ELISA kits were used (GenWay, San Diego, CA, 
USA) according to the manufacturer’s 
instructions.  
Statistics- For statistical analysis, GraphPad Prism 
Software (GraphPad Software, San Diego, CA, 
USA) was used. To compare samples, the paired 
or unpaired t-test was applied and a p-value < 0.05 
was considered to be statistically significant (* p < 
0.05, ** p < 0.01, *** p < 0.001).  All data are 





    MiR-17/92 enhances the acute-phase response 
in HepG2 cells. This study was dedicated to 
investigating the role of miR-17/92 in IL-6 
signaling and acute-phase response. Recently, we 
have demonstrated that STAT3 directly activates 
the transcription of miR-17/92 upon IL-6 
stimulation in human pulmonary arterial 
endothelial cells (12). To address the question 
whether IL-6 enhances the expression of 
miR-17/92 in HepG2 cells and primary 
hepatocytes similarly, IL-6 stimulation 
experiments were performed. As shown in Figure 
1A, HepG2 cells were stimulated for 1h with 
different amounts of IL-6 ranging from 5ng/ml to 
100ng/ml, and expression of the primary transcript 
of miR-17/92 (C13orf25) was assessed as 
described by O’Donnell et al. (11). Treatment with 
the lowest dose of IL-6 led to a small but 
significant up regulation of C13orf25 (1.19±0.13 
fold, p=0.008, Fig. 1A); the strongest induction of 
C13orf25 mRNA levels was found when 
stimulated with 50ng/ml IL-6 (1.54±0.41 fold, 
p=0.012).  
Dose-dependent induction of two acute-phase 
genes (i.e. Hp and FGG) used as positive controls 
is shown in Figure 1B and 1C, respectively. These 
data reflect the potential of IL-6 to efficiently 
stimulate the production of acute-phase genes in 
HepG2 cells. 
Next, we used primary hepatocytes to address the 
role of IL-6 and miR-17/92 in another 
experimental model of the acute-phase response. 
We thus measured the expression levels of 3 
miRNAs derived from miR-17/92 (miR-18a, 
miR-19a, and miR-20a) 24h after IL-6 treatment, 
and found that expression level of all these 
miRNAs was increased in both donors used in this 
study (Fig. 1D). Together with our previous 
findings (12) these data underpin a cell-type 
independent mechanism for the induction of 
miR-17/92 by IL-6.  
    In the further study, we investigated the 
functional consequence of enhanced expression of 
miR-17/92 in HepG2 cells, in particular the 
significances for IL-6 signaling and acute-phase 
response. Therefore, we performed gain-of-
function experiments by transfecting HepG2 cells 
with precursor molecules (pre-miRs) of miR-18a, 
miR-19a, miR-20a, miR-92a (representing the four 
functional miRNA families encoded by 
miR-17/92), and a cocktail of all four. Successful 
over expression of miRNAs was confirmed by 
qPCR (Suppl. Fig. S1). The impact of each 
miRNA on the activity of STAT3 was measured 
by employing a luciferase-based reporter gene 
system consisting of STAT3 sensitive promoter 
sequences of two selected acute-phase genes, i.e. 
Hp and FGG. In scrambled transfected cells, IL-6 
increased the relative Hp promoter activity by 
15.48±4.51 fold as compared to unstimulated 
scrambled transfected cells (Fig. 2A). 
Interestingly, the increase in promoter activity 
upon stimulation with IL-6 was significantly more 
enhanced when HepG2 cells were transfected with 
miR-18a (26.40±4.47 fold, p=0.002), miR-20a 
(21.32±3.04 fold, p=0.032), or with a cocktail of 
all four miRNAs (24.4±5.46 fold, p=0.011). 
Similar results were obtained when the promoter 
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activity of FGG in HepG2 cells was analyzed 
showing a significantly enhanced IL-6 response 
after transfection of miR-18a, miR-20a, miR-92a, 
and of the miR-18a, -19a, -20a, -92a cocktail as 
compared to scrambled transfection (Fig. 2B).  
    To confirm the results of the reporter gene 
assay, mRNA levels of both acute-phase genes in 
HepG2 cells were quantified. IL-6 stimulation for 
4h thus induced the expression of Hp by 4.43±1 
fold in scrambled transfected cells. Over 
expression of miR-18a (6.31±0.75 fold, p=0.001), 
miR-20a (5.92±1.17 fold, p=0.005), miR-92a 
(5.9±0.6 fold, p=0.005), or the miRNA cocktail 
(5.57±1.09 fold, p=0.046) significantly enhanced 
the induction of Hp transcripts (Fig. 2C). 
Quantification of FGG mRNA levels yielded a 
similar expression pattern (Fig. 2D). After 4h of 
stimulation with IL-6, the expression of FGG was 
induced in miR-18a transfected cells (3.89±1.35 
fold, p=0.082) and miR-20a transfected cells 
(3.64±0.51 fold, p=0.03) when compared to 
scrambled transfection (2.86±0.93 fold).  
    Over expression of miR-18a promotes the 
expression of acute-phase proteins. Since miR-18a 
and miR-20a showed the most consistent and 
prominent effects in modulating the acute-phase 
response on mRNA level, we assessed the 
secretion of fibrinogen and Hp into the 
supernatants of HepG2 cells stimulated with IL-6 
for 8h or 24h. Fibrinogen release from miR-18a 
transfected cells collected 8h after stimulation was 
significantly increased both when left 
unstimulated (2170±602 ng/ml, p=0.018) as well 
as in IL-6 stimulated cells (2760±702.6 ng/ml, 
p<0.001) when compared to scrambled 
transfection (unstimulated: 1669±312.1 ng/ml; 
IL-6 stimulated: 2194±556.3 ng/ml; Fig. 3A). 
Enforced expression of miR-20a did not influence 
the release of fibrinogen neither in IL-6 naïve cells 
nor in stimulated conditions. Similarly, after 24h 
of IL-6 stimulation miR-18a over expressing cells 
produced significantly more fibrinogen 
(4899±253.2 ng/ml vs. 4017±173.5 ng/ml in 
scrambled control, p=0.002; Fig. 3A), whereas 
transfection of miR-20a failed to enhance the 
release of fibrinogen. 
    The same supernatants were assessed for Hp 
protein release and, again, we found that miR-18a 
over expression increased the secretion of the 
acute-phase protein (Fig. 3B). In detail, miR-18a 
significantly enhanced Hp release both after 8h 
(166.6±41.46 ng/ml, p=0.02) and after 24h of IL-6 
stimulation (420.8±11.43 ng/ml, p<0.001) when 
compared to scrambled transfected and IL-6 
stimulated cells (139.9±32.6 ng/ml and 368.7±5.25 
ng/ml, respectively). Hp release in miR-20a over 
expressing cells remained unaffected. To confirm 
these findings, identical experiments were 
performed in primary hepatocytes. As shown in 
Figure 3C, the IL-6 induced release of fibrinogen 
after 24h was more pronounced in hepatocytes 
transfected with precursor molecules of miR-18a 
as compared to scrambled control. Similarly, we 
found increased expression of Hp in miR-18a over 
expressing hepatocytes as indicated by Western 
blot (Fig. 3D).    
    The ELISA and Western blot experiments thus 
confirmed the potential of miR-18a but not of 
miR-20a to promote expression and release of 
acute-phase proteins.  
    Conversely, loss of function experiments by 
antagonizing the expression of miR-18a led to a 
decreased acute-phase response in HepG2 cells 
(Suppl. Fig. S2). 
    MiR-18a directly targets PIAS3. The previous 
experiments revealed an enhanced hepatic acute-
phase response upon over expression of miR-18a. 
Since miRNAs have been implicated in the 
repression of gene expression, we speculated that 
miR-18a might target a negative regulator of IL-6 
signaling. Utilizing a computational screening 
(TargetScan, Whitehead Institute for Biomedical 
Research, www.targetscan.org (16)) the 3’UTR of 
PIAS3 was identified to contain a potential 
binding site for miR-18a. PIAS3 is endogenously 
expressed in HepG2 cells and specifically inhibits 
the DNA-binding activity of STAT3 (17). To 
investigate whether miR-18a influences PIAS3 
expression, we measured mRNA levels of PIAS3 
in miR-18a transfected HepG2 cells and primary 
hepatocytes. As shown in Figure 4A, miR-18a 
transfection significantly reduced the expression 
of PIAS3 mRNA in HepG2 cells (by 36±7 %, 
p<0.001) and in hepatocytes from both donors. 
Consistent with these data, Western blot 
experiments showed reduced protein levels of 
PIAS3 in HepG2 cells transfected with pre-
miR-18a (ratio PIAS3/α-tubulin: scrambled 
transfection: 0.52±0.04, pre-miR-18a transfection: 
0.35±0.12, p=0.044, Fig. 4B). To proof specificity 
of the observed reduction of PIAS3, we 
additionally quantified PIAS3 protein expression 
in miR-20a transfected cells. MiR-20a, which was 
not predicted to target PIAS3, did not change the 
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protein expression of PIAS3 (ratio PIAS3/α-
tubulin: 0.53±0.09, p=0.773, Fig. 4B) implicating 
an efficient and specific down regulation of PIAS3 
by miR-18a. 
    To address the question whether the observed 
reduction of PIAS3 expression is directly 
miR-18a-driven, we performed reporter gene 
studies in HEK293 cells. The entire 3’UTR of 
PIAS3 was cloned into the pGL3control vector 
creating a luciferase reporter system with the 
respective seed sequence for miR-18a (Fig. 4D). 
As negative control, the “anti-sense” construct was 
generated (15). In addition, we mutated the 
miR-18a seed match sequence in the “sense” 
construct by introducing four point mutations 
(3’UTR of PIAS3 ΔmiR-18a, Fig. 4D). Co-
transfection of the PIAS3 3’UTR WT construct 
and pre-miR-18a yielded a significantly reduced 
relative luciferase activity (0.6±0.07 fold, p<0.001, 
Fig. 4E). The “anti-sense”, as well as the mutated 
construct, was not affected by over expression of 
miR-18a. These findings imply a direct interaction 
between the 3’UTR of PIAS3 and miR-18a. 
    PIAS3 is an important modulator of the acute-
phase response. So far our data demonstrated that 
miR-18a promotes the acute-phase response and 
directly inhibits PIAS3, a known repressor of 
STAT3 activity. Due to the fact that the role of 
PIAS3 in the acute-phase response was still 
unknown, and to mimic the effects of miR-18a, we 
silenced PIAS3 and, as an additional control, 
STAT3 in HepG2 cells (mRNA levels were 
reduced by 32±12% and 69±6%, respectively, 
p<0.001). Next, we performed reporter gene 
studies to monitor the promoter activity of Hp and 
FGG in siRNA transfected and IL-6 stimulated 
HepG2 cells. The IL-6 induced promoter activity 
of Hp was significantly reduced in STAT3 
silenced cells (7.43±2.01 fold, p<0.001) compared 
to scrambled transfection (21.17±3.55 fold; Fig. 
5A). Conversely, the response to IL-6 was 
increased when the expression of PIAS3 was 
silenced (28.15±3.63 fold, p=0.015). Promoter 
activity studies of FGG revealed a similar result 
showing a significant reduction (silencing of 
STAT3) and increase (silencing of PIAS3) of the 
IL-6 response in HepG2 cells, respectively (Fig. 
5B). To further support these findings, mRNA 
levels of Hp and FGG were measured after 4h of 
IL-6 stimulation. Figure 5C summarizes the 
quantification of Hp mRNA levels showing an 
IL-6 induced up regulation of Hp by 7.32±1.41 
fold in scrambled transfected cells. Transfection of 
STAT3 siRNA reduced the IL-6 induced 
stimulation of Hp mRNA expression (4.78±0.44 
fold, p<0.001); in contrast, the expression of Hp 
was further increased when PIAS3 was silenced 
concomitantly (9.65±2.15, p=0.015). A similar 
expression pattern was detected when the same 
samples were analyzed for the expression of FGG 
mRNA (Fig. 5D). 
    MiR-18a promotes phosphorylation and 
expression of STAT3. The effect of miR-18a on the 
phosphorylation of STAT3 was tested by 
performing Western blot experiments. As shown 
in Fig. 6A, IL-6 treatment induced the 
phosphorylation of STAT3 and was found to be 
more pronounced in pre-miR-18a transfected 
HepG2 cells (ratio STAT3-P/α-tubulin: scrambled 
transfection: 0.84±0.15, pre-miR-18a transfection: 
1.17±0.31, p=0.039, Fig. 6B). Induction peaked 
30min after IL-6 stimulation, indicating enhanced 
activity of STAT3. In addition, the expression of 
STAT3 was increased on protein levels (ratio 
STAT3/α-tubulin: scrambled transfection 
unstimulated: 0.62±0.13, pre-miR-18a transfection 
unstimulated: 1.12±0.26, p=0.002, Fig. 6C) as well 
as on mRNA levels (1.68±0.18 fold, p<0.001, Fig. 
6D) by pre-miR-18a transfection.  
    Taken together, our data present a novel IL-6 – 
miR-17/92 pathway that enhances the expression 
and release of the acute-phase proteins fibrinogen 
and haptoglobin by promoting STAT3 
phosphorylation and inhibition of PIAS3 thereby 
augmenting STAT3 activation. 
   
DISCUSSION 
 
    In this study we demonstrate a novel regulatory 
pathway of the acute-phase response. Briefly, we 
found that IL-6 stimulated the expression of the 
miRNA cluster miR-17/92 in HepG2 cells and 
primary hepatocytes representing a novel positive 
feedback loop of IL-6 signaling through the 
repression of the STAT3 inhibitor PIAS3. Thus, 
over expression of the miR-17/92 derived miR-18a 
enhanced the production of the acute-phase 
proteins fibrinogen and haptoglobin providing 
evidence for an important role of miRNAs in the 
regulation of the inflammatory response. 
    To a substantial extent, the acute-phase 
response is controlled by the cytokine IL-6, which 
is released from monocytes and other immune 
cells during acute and chronic inflammatory 
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disorders (18). In the liver, the acute-phase 
response is initiated by the IL-6 induced 
phosphorylation and dimerization of the 
transcription factor STAT3 which subsequently 
shuttles to the nucleus (3). STAT3 homodimers 
bind to specific DNA sequences in promoter 
regions and stimulate the transcription of IL-6 
target genes (19). We have recently shown that, in 
human pulmonary arterial endothelial cells, 
STAT3 directly activates the transcription of 
miR-17/92 upon stimulation with IL-6 (12). Here, 
analogous stimulation experiments with IL-6 in 
HepG2 cells revealed a dose-dependent up 
regulation of the primary transcript of miR-17/92 
(i.e. C13orf25). Together with our previous results 
(12) the induction of miR-17/92 by IL-6 thus 
appears to be a STAT3 mediated and cell-type 
independent mechanism. In this regard, we 
identified an evolutionarily conserved core 
palindromic TT – AA motif with a 4 bp spacing in 
the promoter of miR-17/92, which is responsible 
for STAT3 binding (12). 
    To maintain a physiological steady-state under 
normal conditions, function and expression of 
STAT3 need to be finely balanced which is mainly 
achieved by the concerted action of intracellular 
feedback loops. We therefore hypothesized that 
the STAT3 regulated miR-17/92 cluster might be 
involved in the feedback signaling of STAT3 as 
well. We thus measured the promoter activity of 
the STAT3 target genes Hp and FGG in HepG2 
cells transfected with miRNA mimics. Over 
expression of miR-18a and miR-20a resulted in 
enhanced activation of STAT3 upon IL-6 
stimulation as shown by promoter studies. These 
results were further confirmed by showing 
increased mRNA expression levels of Hp and 
FGG upon transfection of miR-18a and miR-20a, 
respectively. With respect to these findings we 
conclude that miR-17/92 acts as an enhancer of 
STAT3 activity and represents a positive feedback 
loop in the IL-6 signaling cascade. Interestingly, 
Pichiorri and co-workers demonstrated that 
another miRNA encoded by miR-17/92, miR-19a, 
augments STAT3 activity by targeting SOCS1, a 
known suppressor of STAT3 phosphorylation (8). 
In contrast to these findings, we did not observe 
increased IL-6 signaling in miR-19a transfected 
HepG2 cells. These differences are probably due 
to the respective experimental settings: since 
SOCS1 is part of a negative feedback loop of 
STAT3 activity (6) and, thus, exerts its function 
with temporal delay, the four hours of IL-6 
stimulation employed in the current study might 
be too short to observe a miR-19a mediated effect 
on STAT3 activity. 
    Since miRNAs have mainly been associated 
with the repression of gene expression (7) the 
observed up regulation of acute-phase genes upon 
over expression of miRNAs was most likely due to 
an indirect effect (i.e. the repression of a yet 
undefined inhibitor). A computational approach 
identified PIAS3, which interferes with the DNA 
binding activity of STAT3 (17), to contain a 
potential binding site for miR-18a. Over 
expression of miR-18a decreased the expression of 
PIAS3 both on mRNA (probably due to mRNA 
cleavage) and protein level. Furthermore, by 
performing reporter gene studies comprising the 
3’UTR of PIAS3, we confirmed a direct miR-18a 
driven repression of PIAS3. We demonstrated the 
importance of PIAS3 for acute-phase response by 
showing that knockdown of PIAS3 led to 
enhanced activation of the promoters of FGG and 
Hp and thus increased expression of Hp and FGG 
mRNAs. The correlation between stimulation with 
IL-6 and expression of C13orf25, and PIAS3 was 
further  investigated by kinetical experiments and 
revealed a down regulation of PIAS3 after long-
term stimulation (Suppl. Fig. S3). 
    To determine whether miR-18a also enhances 
the secretion of acute-phase proteins and to put our 
findings into a physiological context, we 
quantified the levels of Hp and fibrinogen in the 
supernatants of pre-miRNA transfected HepG2 
cells. We found the release of Hp and fibrinogen 
to be enhanced by miR-18a in both IL-6 naïve and 
in IL-6 stimulated conditions. These findings 
emphasize the potency of miR-18a as a regulator 
of the acute-phase response via STAT3 signaling. 
Loss of function experiments by antagonizing 
miR-18a to blocking STAT3 signaling was 
performed in HepG2 cells transfected with small 
anti-sense molecules directed against miR-18a 
(anti-miR-18a). These experiments showed 
reduced promoter activity and mRNA expression 
levels of FGG and Hp as well as decreased 
secretion of fibrinogen and Hp in anti-miR-18a 
treated cells. The protein levels of PIAS3, on the 
other hand, were found to be up regulated under 
these conditions. These data confirm the 
pathophysiological role of miR-18a for the IL-6 
signaling cascade and further demonstrate that 
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silencing of miR-18a may provide a useful tool to 
interfere with the hepatic acute-phase response. 
The phosphorylation of tyrosine residue 705 
(Tyr705) of STAT3 is an essential trigger of the 
acute-phase reaction and thus of special 
importance (3). Here, we found that Tyr705 was 
more phosphorylated in pre-miR-18a transfected 
cells indicating enhanced STAT3 activity. These 
findings support the conclusion that miR-18a acts 
as enhancer of the IL-6 pathway. Interstingly, the 
expression of STAT3 by pre-miR-18a transfection 
was found to be increased on mRNA as well as on 
protein levels. Since the inhibitory action of 
PIAS3 affects the DNA binding activity of 
STAT3, one might propose an additional, PIAS3- 
independent effect of miR-18a on Tyr705 
phosphorylation. Whether this effect is due to 
increased expression of the unphosphorylated 
STAT3 substrate remains unclear and needs to be 
addressed by further studies.   
    In addition to miR-18a, the STAT3 dependent 
activation of the Hp and FGG promoters was 
significantly enhanced when HepG2 cells were 
transfected with precursor molecules of miR-20a. 
ELISAs for Hp and fibrinogen, however, did not 
reveal an elevated release of these proteins when 
miR-20a was over expressed. Since two 
independent methods (reporter gene assay and 
qPCR) showed an increase of STAT3 activity by 
miR-20a, we suggest that the failure of increased 
acute-phase protein secretion by miR-20a might be 
due to an impaired protein release, or, 
alternatively, that miR-20a targets not only 
repressors but also activators of the IL-6 
transduction pathway, for example the Janus 
kinase 1 (JAK1). JAK1 is the kinase responsible 
for STAT3 phosphorylation and is also targeted by 
miR-20a (20).  
The most important findings of this study were 
confirmed by performing experiments in an 
additional cell model using primary human 
hepatocytes. By over expressing of miR-18a in 
these cells, we could show that miR-18a augments 
the IL-6 induced acute-phase response by targeting 
the repressor of IL-6 signaling, PIAS3. Similarly, 
IL-6 treatment increased the expression of 
miRNAs derived from the miR-17/92 cluster 
suggesting the presence of a positive feed back-
loop both in primary hepatocytes and in HepG2 
cells.  
    In summary, we propose the following model 
for the regulation of the acute-phase response by 
miR-17/92 (Fig. 7): during states of acute or 
chronic inflammation immune cells secrete IL-6 
which causes the activation of STAT3 in 
hepatocytes. This triggers the production of acute-
phase proteins and their systemic release. At the 
same time the expression of miRNAs derived from 
the cluster miR-17/92 is up regulated. This leads 
to a further augmentation of STAT3 activity 
through the repression of PIAS3 by miR-18a and 
finally contributes to the overwhelming release of 
acute-phase proteins.  
    In conclusion, we identified here a novel IL-6 – 
miR-17/92 pathway, which, through the inhibition 
of PIAS3, enhances the production and release of 
the acute-phase proteins fibrinogen and 
haptoglobin. To our knowledge this is the first 
report on a miRNA mediated regulation of PIAS3 
thus contributing to the understanding of the 
complex regulatory mechanisms within the signal 
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    Fig. 1. Dose-dependent induction of C13orf25 and acute-phase genes by IL-6. HepG2 cells and 
primary hepatocytes were stimulated with IL-6 for 1h or 24h, respectively. (A) The mRNA levels of 
C13orf25 were dose-dependently induced by IL-6, with 50ng/ml of IL-6 yielding the strongest increase of 
C13orf25 (n=7). (B) IL-6 induced the mRNA expression of the acute-phase genes Hp and (C) FGG (n=7). 
(D) IL-6 stimulation (20ng/ml) for 24h led to increased expression levels of miR-18a, miR-19a, and 
miR-20a in primary hepatocytes (n=2). The dashed line indicates unstimulated control cells. The 
respective unstimulated samples were set to 1. Statistical analysis by paired student’s t-test. 
 
    Fig. 2. Effect of miR-17/92 on the acute-phase response in HepG2 cells. HepG2 cells were 
transfected with pre-miRNA (pre-miR-18a, -19a, -20a, -92a, and a cocktail of all four) or scrambled 
negative control. (A) Promoter activity of Hp was assessed by co-transfection of a luciferase-based vector 
system comprising 878 bp of the Hp promoter sequence. 4h of IL-6 stimulation (20ng/ml) induced 
relative luciferase activity in all samples, while the IL-6 response was more pronounced in miR-18a, 
miR-20a, and the miRNA cocktail transfected cells (n=5). (B) A luciferase-based reporter gene system 
consisting of the promoter sequence of FGG (578 bp) was co-transfected in HepG2 cells. The response to 
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4h of IL-6 stimulation was enhanced by co-transfection of miR-18a, miR-20a, miR-92a, and a cocktail of 
all as compared to scrambled control (n=7). (C) Quantification of the mRNA levels of Hp after 4h of IL-6 
stimulation (20ng/ml) showed a similar result as the respective reporter gene studies. The IL-6 inducible 
effect on Hp transcription was significantly enhanced by transfection of miR-18a, miR-20a, miR-92a, and 
the cocktail of all four miRNAs (n=6). (D) Identical samples showing significant alteration of the FGG 
mRNA expression by IL-6 in miR-20a transfected cells (n = 6). The respective unstimulated samples 
were set to 1. Statistical analysis by unpaired student’s t-test.  
 
    Fig. 3. Over expression of miR-18a promotes the expression and release of acute-phase proteins. 
Protein levels of fibrinogen and Hp of pre-miRNA transfected HepG2 cells and hepatocytes were 
quantified by ELISA or Western blot. (A) Release of fibrinogen into the supernatants after 8h and 24h of 
IL-6 stimulation (20ng/ml) was significantly increased in cells over expressing miR-18a as shown by 
ELISA. MiR-20a transfection failed to increase the release of fibrinogen (n≥5). (B) The same 
supernatants were assessed for quantification of Hp protein levels showing enhanced secretion of Hp after 
8h and 24h of IL-6 stimulation when miR-18a was over expressed. Transfection of miR-20a did not 
change the release of Hp (n≥5). (C) Primary hepatocytes were transfected with pre-miR-18a and 
stimulated with IL-6 (20ng/ml) for 24h. The total amount of fibrinogen in supernatants was quantified by 
ELISA showing that the IL-6 induced release of fibrinogen was enhanced in hepatocytes transfected with 
pre-miR-18a (n=2). (D) The same cells were analyzed for protein levels of haptoglobin using Western 
blot. The expression of haptoglobin was increased by miR-18a transfection as compared to scrambled 
transfection (n=2). Statistical analysis by paired student’s t-test.  
 
    Fig. 4. PIAS3 is a direct target of miR-18a. (A) MiR-18a transfected HepG2 cells revealed a 
significant down regulation of PIAS3 mRNA levels compared to scrambled control (n=7). The mRNA 
levels of PIAS3 were also found to be decreased by miR-18a transfection in primary hepatocytes (n=2). 
(B) Western blot confirmed the reduced expression of PIAS3 on protein level in HepG2 cells as assessed 
by densitometric analysis (n=4). Specific miR-18a-mediated down regulation of PIAS3 was proven by 
transfection of a non-predicted miRNA, miR-20a, showing no alterations in the protein expression of 
PIAS3. (C) Western Blots used for densitometric analysis are shown (n=4). (D) TargetScan prediction 
software identified one seed match of miR-18a in the 3’UTR of PIAS3; the predicted base pairing of 
PIAS3 mRNA and miR-18a is shown. The entire 3’UTR of PIAS3 was used for reporter gene studies and 
the predicted miR-18a seed sequence was destroyed by introducing four point mutations. (E) Reporter 
gene studies in HEK293 cells showed that co-transfection of miR-18a significantly decreased the relative 
luciferase activity compared to scrambled transfection. The “anti-sense” construct as well as the mutated 
construct (ΔmiR-18a) were not affected by over expression of miR-18a (n=7). Statistical analysis by 
paired student’s t-test (A, E; scrambled transfection was set to 1) or by unpaired student’s t-test (B). 
 
    Fig. 5. PIAS3 is an important mediator of the acute-phase response. HepG2 cells were transfected 
with siRNAs targeting PIAS3 (si_PIAS3) and STAT3 (si_STAT3). (A) IL-6 stimulation (20ng/ml) for 4h 
activated the promoter of Hp in all samples with silencing of STAT3 reducing the activity of luciferase as 
compared to scrambled transfection. Conversely, silencing of PIAS3 increased the relative luciferase 
activity (n=5). (B) Promoter studies of FGG revealed a similar pattern of activation showing a significant 
reduction (si_STAT3) and enhancement (si_PIAS3) of the IL-6 response in HepG2 cells, respectively 
(n=7). (C) mRNA levels of Hp after 4h of IL-6 stimulation were significantly decreased (si_STAT3) or 
increased (si_PIAS3) compared to scrambled transfection (n=9). (D) The same samples were analyzed for 
expression of FGG mRNA expression showing a similar expression pattern (n=9). The respective 
unstimulated samples were set to 1. Statistical analysis by unpaired student’s t-test. 
 
     Fig. 6. MiR-18a promotes phosphorylation and expression of STAT3. HepG2 cells were 
transfected with pre-miR-18a or scrambled negative control, serum starved and stimulated with IL-6 
(20ng/ml) for 30min, 1h or 4h. (A) Western blot experiments were performed to analyze phosphorylation 
and expression of STAT3; two representative Western blots are shown. (B) Phosphorylation of STAT3 
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(Tyr705) was markedly enhanced in pre-miR-18a transfected cells as compared to scrambled transfection. 
Densitometric analysis revealed a significant increase after 30min of IL-6 stimulation (n=6). 
(C) Transfection of miR-18a led to a significant up regulation of protein levels of STAT3 in IL-6 naïve as 
well as in IL-6 stimulated HepG2 cells. Densitometric analysis is shown (n=6). (D) The mRNA levels of 
STAT3 were found to be up regulated in miR-18a over expressing cells (n=7). Statistical analysis by 
unpaired student’s t-test. 
 
    Fig. 7. Regulation of acute-phase gene expression by miR-17/92 through a positive feedback loop 
involving PIAS3. We propose the following model for the regulation of the acute-phase response by the 
miR-17/92 cluster: IL-6, released from immune cells, activates STAT3 in hepatocytes thus triggering the 
expression of acute-phase genes and the miRNA cluster miR-17/92. In turn, miR-18a targets the STAT3 
inhibitor PIAS3, which leads to the enhanced activation of STAT3 and, thus, results in an increased 
release of acute-phase proteins. 
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